Friday, 6 June 2014

Unexpected MEK1 Mutations Not Cause of Potent Melanoma Drug Resistance

Not from ASCO but on my list of noteworthy!

The previously held belief (it was very much thought of the day when Peter was diagnosed with Melanoma) that resistance to BRAF inhibitors (like Dabrafenib or Vemurafenib) is caused by the acquisition of new mutations in MEK1 turns out not to be true as patients who have mutations both in BRAF and MEK1 from the beginning still respond to the drugs-

read the details here!

No comments:

Post a Comment